RESULTS
Of the 61 patients who were admitted to our clinic for Peyronie’s
disease, 48 patients who met the inclusion criteria were included in the
study. All patients completed the 8-week treatment protocol. No patients
were excluded from the study because no serious side effects or
worsening of symptoms were observed during the protocol. The mean age
was 61.1 (43-78). The average time from the onset of complaints was 3.4
months (0-9). Curvature was dorsal in 19 (39.6%) patients, ventral in 5
(10.4%) patients, lateral in 12 (25%) patients, and dorsolateral in 12
(25%) patients. The average plaque size before treatment was 13.6 mm
(7.1-16.8), and after treatment, this value decreased to 10.8 mm
(4.3-14.6) (p = 0.025) (Figure 1). In 35 (72.9%) of the 48 patients, a
decrease in plaque size was seen after treatment. Plaque size did not
increase in for any of the patients after treatment. The mean curvature
angle was 55.7 degrees (35-85) before treatment, whereas this value
decreased to 52.5 degrees (33-85) after treatment. In 8 (16.7%) of the
48 patients, the curvature angle was reduced, but this decrease was not
statistically significant (p:0.07) (Figure 2). In five patients
(10.4%), curvature angle was increased. This increase was no more than
10 degrees. The changes in plaque size and curvature angle did not show
any statistically significant difference with respect to curvature
direction (p = 0.145). No local or systemic side effects or
complications were observed during or after drug administration,
excluding pain resulting from the injection of the drug.
The average IIEF-5 score before treatment was 18.1 (10-25). This score
increased to 20.2 (10-25) after treatment. However, this rise was not
statistically significant (p = 0.069). The PDQS score was 12.3 (4-18) on
average, and this value decreased significantly to 8.9 (0-14) after
treatment (p = 0.001). The PDQP score average was 19.1 (12-26) before
treatment and significantly decreased to 9.6 (0-21) after treatment (p
< 0.001). Finally, the PDQB score decreased significantly
after treatment, as did the other scores. Before treatment, this value
was 6.2 (4-12), and after treatment, it was 4.4 (2-10) (p = 0.045)
(Figure 3).